Reply to: "Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations"

Mov Disord. 2022 May;37(5):1119-1120. doi: 10.1002/mds.28995.

Authors

Daniel Macías-García^{1

2}, María Teresa Periñán^{1

2}, Laura Muñoz-Delgado^{1

2}, Silvia Jesús^{1

2}, María Valle Jimenez-Jaraba¹, Dolores Buiza-Rueda^{1

2}, Marta Bonilla-Toribio^{1

2}, Astrid Adarmes-Gómez^{1

2}, Fátima Carrillo^{1

2}, Pilar Gómez-Garre^{1

2}, Pablo Mir^{1

2

3}

Affiliations

¹ Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.
² Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
³ Departamento de Medicina, Facultad de Medicina, Universidad de Sevilla, Seville, Spain.

PMID: 35587631
DOI: 10.1002/mds.28995

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Humans
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 / genetics
Mutation / genetics
Parkinson Disease* / complications
Parkinson Disease* / genetics

Substances

LRRK2 protein, human
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2